Revenue
2017
2018
2019
2020
2021
2022
2023
2024
RedHill Biopharma Ltd. (RDHL)
Price—Loading quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
Financial statements
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.0M | $6.5M | $61.8M | $85.8M | $64.4M | $6.3M | $8.4M | $4.0M | $101,000 | $3,000 |
| Gross profit | $4.9M | $3.1M | $28.5M | $36.4M | $27.5M | $4.0M | $5.5M | $1.9M | $101,000 | $3,000 |
| Research & development | $1.6M | $3.5M | $7.3M | $29.5M | $16.5M | $17.4M | $24.9M | $33.0M | $25.2M | $17.8M |
| Operating income | −$14.6M | $12.6M | −$42.8M | −$81.1M | −$63.7M | −$43.2M | −$39.3M | −$52.0M | −$30.5M | −$22.0M |
| Net income | −$8.3M | $23.9M | −$71.7M | −$97.7M | −$76.2M | −$42.3M | −$38.8M | −$45.5M | −$29.4M | −$21.1M |
| Basic EPSper diluted share | $0.00 | $0.01 | -$0.12 | -$0.21 | -$0.21 | -$0.14 | -$0.17 | -$0.26 | -$0.23 | -$0.19 |
| Diluted EPSper diluted share | $0.00 | $0.01 | -$0.12 | -$0.21 | -$0.21 | -$0.14 | -$0.17 | -$0.26 | -$0.24 | -$0.19 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 6, 2026Form 4 | Raday GileadChief Operating Officer | SellOrdinary Shares | 15.74M | $0.00 | $0.00 | 261.06M |